Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy. Yang, J., Popat, S., Georgiou, P., Miyamoto, E., Isaacson, J. D., Wakelee, H. A. AMER SOC CLINICAL ONCOLOGY. 2015
View details for Web of Science ID 000358036904858